Vascular Contributions to Cognitive Impairment after Adverse Pregnancy Outcomes: the nuMoM2b-Heart Health Study
血管对不良妊娠结果后认知障碍的影响:nuMoM2b-心脏健康研究
基本信息
- 批准号:10559052
- 负责人:
- 金额:$ 6.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-02 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:Academic Medical CentersAdverse eventAgeAgingAncillary StudyBackBiological MarkersBrain imagingCardiac healthCardiovascular systemCerebral small vessel diseaseCharacteristicsChildCognitionCollectionConceptionsDataDementiaDevelopmentDiscipline of obstetricsEnrollmentFetal Growth RetardationFutureGoalsHypertensionImpaired cognitionInterventionInvestmentsLifeMediatingMedical centerMonitorMothersNeurocognitiveNulliparityOutcome StudyParticipantPersonsPhenotypePlacenta DiseasesPopulationPre-EclampsiaPregnancyPregnancy OutcomePremature BirthPrevention strategyProspective cohortRiskSiteUniversitiesVascular Cognitive ImpairmentVirulence FactorsVisitWhite Matter HyperintensityWomanadverse pregnancy outcomebrain magnetic resonance imagingcardiovascular risk factorcerebrovascularcohortdementia riskhigh riskindexingmagnetic resonance imaging biomarkerpredictive modelingprospectivesexvascular cognitive impairment and dementiavascular risk factor
项目摘要
PROJECT SUMMARY/ABSTRACT
Vascular contributions to cognitive impairment and dementia (VCID) are now recognized as a key pathogenic
factor in dementia, and represent a promising target for intervention. Adverse pregnancy outcomes (APOs),
such as preeclampsia, preterm delivery, and fetal growth restriction, are associated with future maternal
cardiovascular and cerebrovascular risk. However, the impact of APOs on maternal VCID remains
unexamined. Most existing women's cardiovascular and aging cohorts lack rigorously phenotyped,
prospectively collected pregnancy data, and the impact of maternal factors that may predispose to both APOs
and VCID is not well understood. From 2010-2013, the Nulliparous Pregnancy Outcomes Study Monitoring
Mothers-to-be (nuMoM2b) study enrolled a diverse cohort of 10,037 healthy women at 8 US academic medical
centers, who were followed from early in conception through the delivery of their first child. Several years later,
the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be Heart Health Study (nuMoM2b-HHS)
brought back 4,475 nuMoM2b women for a second study wave, to characterize subsequent pregnancy
outcomes and accumulation of cardiovascular risk factors following pregnancy. A third study wave of in-person
visits will begin in early 2022. In this ancillary study, we propose to conduct neurocognitive assessments on all
nuMoM2b-HHS participants during this third study wave. We will perform brain magnetic resonance imaging
(MRI) on a sub-cohort of 250 women followed at the Columbia University Irving Medical Center study site,
including all who experienced APOs in the index pregnancy. The overall goal of the study is to capitalize on
this unique obstetric cohort to determine the impact of APOs on long term maternal VCID, through the
following specific aims: (1) Investigate the impact of APOs on maternal cognition 10-15 years after delivery by
comparing global cognition scores between women who experienced APOs and women who did not; (2)
Determine the impact of APOs on MRI biomarkers of maternal VCID, including white matter hyperintensity
volume and additional markers of cerebral small vessel disease. We hypothesize that the association of APOs
with VCID markers will be partially mediated by development of new hypertension after the index pregnancy.
As an exploratory aim, we will use deep pregnancy phenotyping, including maternal characteristics, biomarkers
of ischemic placental disease and APOs, to create a VCID prediction model. This will be the first US study to
use prospectively collected pregnancy data to investigate the impact of APOs, a sex-specific vascular risk
factor, on VCID in women. Understanding the effects of APOs on early markers of VCID could help us identify
women early in life who are at higher risk of dementia, and develop preventive strategies to thwart the
progression of cognitive decline in this population. In addition, the collection of neurocognitive assessments on
the entire nuMoM2b-HHS cohort during this study wave is an important investment, which will provide baseline
data for future studies as these women continue to age.
项目总结/摘要
血管对认知障碍和痴呆(VCID)的贡献现在被认为是一个关键的致病因素,
痴呆症的因素,并代表了一个有希望的干预目标。不良妊娠结局(APO),
例如先兆子痫、早产和胎儿生长受限,与未来母亲
心血管和脑血管风险。然而,APO对母体VCID的影响仍然存在,
未经检查大多数现有女性的心血管和衰老队列缺乏严格的表型分析,
前瞻性收集妊娠数据,以及可能导致两种APO的母体因素的影响
并且VCID没有被很好地理解。2010-2013年未产妊娠结局研究监测
准妈妈(nuMoM 2b)研究在8所美国学术医学院招募了10,037名健康女性的多元化队列
这些研究人员从怀孕早期到第一个孩子的出生都进行了跟踪。几年后,
未产妊娠结局研究:监测准妈妈心脏健康研究(nuMoM 2b-HHS)
在第二次研究中,4,475名nuMoM 2b妇女被带回,以描述随后怀孕的特征。
妊娠后心血管危险因素的累积和结局。第三波面对面学习
访问将于2022年初开始。在这项辅助研究中,我们建议对所有人进行神经认知评估。
nuMoM 2b-HHS参与者在这第三个研究波。我们将进行脑部磁共振成像
(MRI)在哥伦比亚大学欧文医学中心的研究地点,
包括所有在首次妊娠中发生APO的患者。这项研究的总体目标是利用
这一独特的产科队列,以确定APO对长期孕产妇VCID的影响,通过
以下具体目标:(1)调查APO对分娩后10-15年母亲认知的影响,
比较经历过APO的女性和没有经历过APO的女性之间的整体认知得分;(2)
确定APO对母体VCID MRI生物标志物的影响,包括白色高信号
脑小血管疾病的体积和其他标志物。我们假设载脂蛋白结合
与VCID标志物的结合将部分由指数妊娠后新的高血压的发展介导。
作为一个探索性的目标,我们将使用深妊娠表型,包括母体特征,生物标志物
缺血性胎盘疾病和APO的关系,以建立VCID预测模型。这将是美国第一项研究,
使用前瞻性收集的妊娠数据研究APO的影响,APO是一种性别特异性血管风险
因素,对女性的VCID。了解载脂蛋白对VCID早期标志物的影响可以帮助我们识别
老年痴呆症风险较高的妇女,并制定预防战略,
认知能力下降的进展。此外,收集神经认知评估,
在本研究波期间,整个nuMoM 2b-HHS队列是一项重要的投资,它将提供基线
随着这些女性年龄的增长,未来的研究数据。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eliza C Miller其他文献
Associations between adverse pregnancy outcomes and cognitive impairment and dementia: a systematic review and meta-analysis
不良妊娠结局与认知障碍和痴呆之间的关联:系统评价和荟萃分析
- DOI:
10.1016/j.lanhl.2024.100660 - 发表时间:
2024-12-01 - 期刊:
- 影响因子:14.600
- 作者:
Eliza C Miller;Patrick Conley;Mohammad Alirezaei;Katrin Wolfova;Mitzi M Gonzales;Zaldy S Tan;Sarah E Tom;Lynn M Yee;Adam M Brickman;Natalie A Bello - 通讯作者:
Natalie A Bello
Eliza C Miller的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eliza C Miller', 18)}}的其他基金
PROtecting Maternal brains from Injury and Stroke (PROMIS): a Single-center Phase 2 Clinical Trial
保护母亲大脑免受损伤和中风 (PROMIS):单中心 2 期临床试验
- 批准号:
10575711 - 财政年份:2023
- 资助金额:
$ 6.43万 - 项目类别:
Vascular Contributions to Cognitive Impairment after Adverse Pregnancy Outcomes: the nuMoM2b-Heart Health Study
血管对不良妊娠结果后认知障碍的影响:nuMoM2b-心脏健康研究
- 批准号:
10675067 - 财政年份:2021
- 资助金额:
$ 6.43万 - 项目类别:
Vascular Contributions to Cognitive Impairment after Adverse Pregnancy Outcomes: the nuMoM2b-Heart Health Study
血管对不良妊娠结果后认知障碍的影响:nuMoM2b-心脏健康研究
- 批准号:
10517965 - 财政年份:2021
- 资助金额:
$ 6.43万 - 项目类别:
Vascular Contributions to Cognitive Impairment after Adverse Pregnancy Outcomes: the nuMoM2b-Heart Health Study
血管对不良妊娠结果后认知障碍的影响:nuMoM2b-心脏健康研究
- 批准号:
10275504 - 财政年份:2021
- 资助金额:
$ 6.43万 - 项目类别:
Vascular Contributions to Cognitive Impairment after Adverse Pregnancy Outcomes: the nuMoM2b-Heart Health Study
血管对不良妊娠结果后认知障碍的影响:nuMoM2b-心脏健康研究
- 批准号:
10445312 - 财政年份:2021
- 资助金额:
$ 6.43万 - 项目类别:
Pregnancy complications and the development of Alzheimer's disease and related dementias in women in the Adult Changes in Thought study
成人思维变化研究中女性妊娠并发症以及阿尔茨海默病和相关痴呆症的发展
- 批准号:
10055554 - 财政年份:2020
- 资助金额:
$ 6.43万 - 项目类别:
Neurovascular Unit Dysfunction in Women with Severe Preeclampsia
严重先兆子痫女性的神经血管单元功能障碍
- 批准号:
10186050 - 财政年份:2020
- 资助金额:
$ 6.43万 - 项目类别:
Pregnancy complications and the development of Alzheimer's disease and related dementias in women in the Adult Changes in Thought study
成人思维变化研究中女性妊娠并发症以及阿尔茨海默病和相关痴呆症的发展
- 批准号:
10271262 - 财政年份:2020
- 资助金额:
$ 6.43万 - 项目类别:
Neurovascular Unit Dysfunction in Women with Severe Preeclampsia
严重先兆子痫女性的神经血管单元功能障碍
- 批准号:
10404069 - 财政年份:2019
- 资助金额:
$ 6.43万 - 项目类别:
Neurovascular Unit Dysfunction in Women with Severe Preeclampsia
严重先兆子痫女性的神经血管单元功能障碍
- 批准号:
10622557 - 财政年份:2019
- 资助金额:
$ 6.43万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 6.43万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 6.43万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 6.43万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 6.43万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 6.43万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 6.43万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 6.43万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 6.43万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 6.43万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 6.43万 - 项目类别:














{{item.name}}会员




